ERBB2 and breast carcinoma: The activation of FOXO3a, triggered by increased IGF2 expression, is modulated by miR-128-3p, miR-30a and miR-193-5p, which target IRS1 and IGF2, maintaining HER2-positive breast cancer cells responsive to trastuzumab.